Ocular Surface Disease

The first patients were dosed in the global phase 3 ORBIT trial evaluating linsitinib as an oral therapy for thyroid eye disease.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Cataract safety, Glaucoma drugs and MIGS, plus Artificial Intelligence debates and retina breakthroughs—key FDA moves and trial updates in ophthalmology.

Bausch + Lomb advances dual-action dry eye drop to phase 3 and reports positive phase 1b data for TRPV1 antagonist BL1332

Angela Y. Zhu, MD, of Bascom Palmer Eye Institute, explains how to distinguish eye allergy from vision-threatening VKC and AKC in children and when steroid-sparing therapy and referral are warranted.

Alice Epitropoulos, MD, shares cases of Demodex blepharitis and reflects on how lotilaner has changed treatment before ocular surgery.

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

A study of YB-101, a potential treatment for both Graves' disease and thyroid eye disease, has begun dosing the first patients. The molecule receive Fast Track Designation from the FDA.

A newly developed diagnostic system, CaptureTumor (CaT), driven by artificial intelligence (AI) and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation” for detecting rare ocular surface malignancies.

Two cases illustrate how recognizing and treating Demodex can change surgical outcomes and resolve chronic dry eye disease.

Proactive strategies enhance comfort, adherence, and long-term glaucoma control

According to the company, this meeting helped to provide a “clear path forward” for CBT-004 in its projected phase 3 study

Harvard researchers used data to shed light on pediatric neurotrophic keratopathy, revealing key insights into prevalence, vision outcomes, and treatment approaches.

A recent study reveals significant ocular complications from monkeypox, highlighting the need for enhanced eye health strategies in affected regions.

Sezen Karakus, MD, highlights options including compounded cyclosporine, autologous serum drops, recombinant human nerve growth factor, and newer topical agents to manage refractory or neurotrophic dry eye.

Alternative management may avoid current concerns found with antibiotics.

Tips for optimizing surgical techniques to reduce recurrence and enhance outcomes.

The trial is being discontinued based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the trials for “futility."

A phase IV study in China found that 22 of 26 patients achieved complete healing of a persistent corneal epithelial defect or corneal ulcer after 8 weeks.

A study from a tertiary eye hospital suggests that effective keratitis management may have the potential to restore vision.

Under the terms of the agreement Iolyx Therapeutics has granted Théa exclusive worldwide development and commercialization rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases.

Real-world insights emphasize identifying underlying causes to tailor treatment.